000141131 001__ 141131
000141131 005__ 20240229105119.0
000141131 0247_ $$2doi$$a10.1177/2050640618784053
000141131 0247_ $$2pmid$$apmid:30288285
000141131 0247_ $$2pmc$$apmc:PMC6169043
000141131 0247_ $$2ISSN$$a2050-6406
000141131 0247_ $$2ISSN$$a2050-6414
000141131 037__ $$aDKFZ-2018-01662
000141131 041__ $$aeng
000141131 082__ $$a610
000141131 1001_ $$0P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aGies, Anton$$b0$$eFirst author$$udkfz
000141131 245__ $$aFecal immunochemical test for hemoglobin in combination with fecal transferrin in colorectal cancer screening.
000141131 260__ $$aLondon$$bSage$$c2018
000141131 3367_ $$2DRIVER$$aarticle
000141131 3367_ $$2DataCite$$aOutput Types/Journal article
000141131 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1659699977_13808
000141131 3367_ $$2BibTeX$$aARTICLE
000141131 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000141131 3367_ $$00$$2EndNote$$aJournal Article
000141131 520__ $$aFecal transferrin has been suggested as a complementary or even superior marker for early detection of colorectal cancer (CRC) besides fecal hemoglobin. We aimed to evaluate both markers individually and in combination in a large cohort of participants of screening colonoscopy.Precolonoscopy stool samples were obtained from participants of screening colonoscopy and frozen at -80℃ until blinded analysis, using a dual-quantitative fecal immunochemical test (FIT) for hemoglobin and transferrin. Sensitivity, specificity and area under the curve (AUC) were calculated for CRC and advanced adenoma (AA).A total of 1667 participants fulfilled our inclusion criteria. All individuals with advanced neoplasm (AN) (16 CRC, 200 AA) and 300 randomly selected participants without AN were included. Mean age was 63 years and 56% were male. The AUC for CRC and AA was 92% and 68%, respectively, for hemoglobin vs. 79% and 58%, respectively for transferrin. Combination of both markers yielded an AUC for CRC and AA of 92% and 68%, respectively.FIT for hemoglobin shows better diagnostic performance than FIT for transferrin for the detection of ANs (both proximal and distal neoplasms), and a combination of both markers does not improve the diagnostic performance.
000141131 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000141131 588__ $$aDataset connected to CrossRef, PubMed,
000141131 7001_ $$0P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aCuk, Katarina$$b1$$udkfz
000141131 7001_ $$0P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aSchrotz-King, Petra$$b2$$udkfz
000141131 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b3$$eLast author$$udkfz
000141131 773__ $$0PERI:(DE-600)2728585-6$$a10.1177/2050640618784053$$gVol. 6, no. 8, p. 1223 - 1231$$n8$$p1223 - 1231$$tUnited european gastroenterology journal$$v6$$x2050-6414$$y2018
000141131 909CO $$ooai:inrepo02.dkfz.de:141131$$pVDB
000141131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6d4d6a0e2d726f899086ca98cd560922$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000141131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0a8ada1f5d2ea05fc3af10cd808bfa9a$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000141131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)01ef71f71b01a3ec3b698653fd43fe86$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000141131 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000141131 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000141131 9141_ $$y2018
000141131 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz
000141131 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000141131 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bUNITED EUR GASTROENT : 2017
000141131 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000141131 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000141131 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000141131 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000141131 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000141131 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000141131 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000141131 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000141131 9201_ $$0I:(DE-He78)G110-20160331$$kG110$$lPräventive Onkologie$$x1
000141131 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000141131 980__ $$ajournal
000141131 980__ $$aVDB
000141131 980__ $$aI:(DE-He78)C070-20160331
000141131 980__ $$aI:(DE-He78)G110-20160331
000141131 980__ $$aI:(DE-He78)L101-20160331
000141131 980__ $$aUNRESTRICTED